[Comparative analysis of clinical diagnosis and treatment guidelines for drug-induced liver injury at home and abroad].

Drug-induced liver injury influencing factors are complex and have diverse clinical manifestations. Simple and reliable diagnostic methods are still deficient, and further classification of toxicological mechanisms is required. There are numerous pertinent discrepancies between domestic and international guidelines aimed at drug-induced liver injury diagnosis and treatment, with partial to no consensus on the content. The American Gastroenterological Association's 2021 Clinical Guidelines, the Asia-Pacific Association for the Study of the Liver's 2021 Consensus Guidelines, the Council for International Organizations of Medical Sciences' 2020 International Consensus, the European Society's Hepatology Committee's 2019 Clinical Practice Guidelines, and the 2015 Chinese Medical Association Guidelines are five influential clinical guidelines on drug-induced liver injury at home and abroad. The epidemiology, risk factors, diagnosis and evaluation, treatment management, and other contents, particularly traditional Chinese medicine, were compared and analyzed using other relevant consensus opinions or guidelines in order to improve understanding and provide a reference for clinical diagnosis and treatment of drug-induced liver injury.药物性肝损伤的影响因素复杂，临床表现多样，尚缺乏简便可靠的诊断方法，毒理机制等也有待进一步明确。针对药物性肝损伤的诊治，国内外相关指南存在诸多差异，部分内容未形成共识。现选择国内外影响较大的5个药物性肝损伤临床指南——2021美国胃肠病学会临床指南、2021亚太肝病学会共识指南、2020国际医学组织理事会药物性肝损伤国际共识、2019欧洲肝病学会临床实践指南、2015中华医学会药物性肝损伤诊治指南等，并参考其他相关共识意见或指南，就药物性肝损伤尤其中草药肝损伤的流行病学、风险因素、诊断评估、治疗管理等内容进行比较分析，以期提高认识，为药物性肝损伤的临床诊断和治疗提供参考。.